Tag Archives: Supreme Court

“Obamacare” Survives – Including Path to Generic Biologicals

Biotech patent attorneys rejoice – no matter if you represent generic companies or NDA holders,  the 5-4 decision of the Supreme Court upholding the “individual mandate” – not under the commerce clause, but as an appropriate use of Congress’ power to … Continue reading

Posted in Follow-On Biologics | Tagged , , , , , , , | Leave a comment

Lilly Files Amicus Brief in Myriad Remand – With Friends Like This…

Following its reversal of the Fed. Cir.’s decision in Mayo v. Prometheus (“Mayo”), the Supreme Court GVR’d in response to AMP’s (read: ACLU’s) appeal of Myriad’s claims to isolated DNA sequences and to a method of screening potential anti-cancer drugs … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , | Leave a comment

Prometheus Unbound – Are Methods Of Medical Treatment The Next “Targets”?

In my March post “Unnatural Acts – Patenting Diagnostic Tests Post-Prometheus” I wrote: “I have been trying to formulate diagnostic claims that would pass muster post-Prometheus and I am having trouble. If a researcher discovers the marker, the researcher should … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , | 2 Comments

Prometheus Q/A Results: Does Patent Eligibility Impact Biotech Research?

A guest post from shareholder Robin Chadwick of SLW. A quick survey of folks who read this blog indicates that funding for 5 Buy Cheap Cialis Soft 0% of respondents’ R&D is affected by whether or not a project was … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , | Leave a comment